Findings

What do systematic reviews say?

10 questions · 17 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 5.9%GRADE not reported 0 · 0%Very low 6 · 35.3%Low 5 · 29.4%Moderate 5 · 29.4%High 0 · 0%

Hormonal therapy vs placebo or no intervention

Effect on later sexual function · symptomatic or early postmenopausal women1.

4 findings from 1 review

Hormone therapy for sexual function in perimenopausal and postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 699 participants
Moderate
Hormone therapy for sexual function in perimenopausal and postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 883 participants
Very low
Hormone therapy for sexual function in perimenopausal and postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 215 participants
Very low

Show 1 more finding

Hormone therapy for sexual function in perimenopausal and postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 542 participants
Very low

Hormonal therapy vs placebo or no intervention

Effect on later sexual function · Postmenopausal women

5 findings from 1 review

Hormone therapy for sexual function in perimenopausal and postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 272 participants
Very low
Hormone therapy for sexual function in perimenopausal and postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 608 participants
Moderate
Hormone therapy for sexual function in perimenopausal and postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 104 participants
Very low

Show 2 more findings

Hormone therapy for sexual function in perimenopausal and postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 105 participants
Very low
Hormone therapy for sexual function in perimenopausal and postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1525 participants
Low

Hormonal therapy vs placebo or no intervention

Estrogen + progestogens · symptomatic or early postmenopausal women1.

The review found no eligible studies for this question.

1 finding from 1 review

Hormone therapy for sexual function in perimenopausal and postmenopausal women 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Death (all causes)

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower time to death due to any cause (absolute effect size estimates based… compared with ADT only (moderate certainty).

1 finding from 1 review

Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
HR 0.77 [0.68, 0.87]
3 studies · 2261 participants
Moderate

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Adverse events grade 3 to 5 Range of

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher grade III to V adverse events compared with ADT only (low certainty).

1 finding from 1 review

Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
RR 2.98 [2.19, 4.04]
1 study · 375 participants
Low

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Prostate cancer‐specific death5

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower prostate cancer‐specific death5 compared with ADT only (moderate certainty).

1 finding from 1 review

Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
RR 0.79 [0.7, 0.89]
3 studies · 2261 participants
Moderate

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Time to progression

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) probably leads to lower time to progression (absolute effect size estimates based on… compared with ADT only (moderate certainty).

1 finding from 1 review

Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
HR 0.63 [0.56, 0.71]
3 studies · 2261 participants
Moderate

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Withdrawals due to adverse events

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher discontinuation due to adverse events compared with ADT only (low certainty).

1 finding from 1 review

Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
RR 79.41 [4.92, 1282.78]
1 study · 385 participants
Low

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

All adverse events

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) may leads to higher all adverse events compared with ADT only (low certainty).

1 finding from 1 review

Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
RR 1.11 [1.06, 1.17]
1 study · 375 participants
Low

Early taxane‐based chemotherapy and androgen deprivation therapy (ADT) vs ADT only

Quality of life at 12 months (

1 finding from 1 review

Taxane‐based chemohormonal therapy for metastatic hormone‐sensitive prostate cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 790 participants
Low